Gefitinib versus placebo in completely resected non-small-cell lung cancer: results of the NCIC CTG BR19 study

Survival of patients with completely resected non-small-cell lung cancer (NSCLC) is unsatisfactory, and in 2002, the benefit of adjuvant chemotherapy was not established. This phase III study assessed the impact of postoperative adjuvant gefitinib on overall survival (OS). Patients with completely r...

Full description

Saved in:

Bibliographic Details
Published in:	Journal of clinical oncology Vol. 31; no. 27; p. 3320
Main Authors:	Goss, Glenwood D, O'Callaghan, Chris, Lorimer, Ian, Tsao, Ming-Sound, Masters, Gregory A, Jett, James, Edelman, Martin J, Lilenbaum, Rogerio, Choy, Hak, Khuri, Fadlo, Pisters, Katherine, Gandara, David, Kernstine, Kemp, Butts, Charles, Noble, Jonathan, Hensing, Thomas A, Rowland, Kendrith, Schiller, Joan, Ding, Keyue, Shepherd, Frances A
Format:	Journal Article
Language:	English
Published:	United States 20.09.2013
Subjects:	Aged Antineoplastic Agents - adverse effects Antineoplastic Agents - therapeutic use Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - pathology Carcinoma, Non-Small-Cell Lung - surgery Chemotherapy, Adjuvant Disease-Free Survival Double-Blind Method Female Humans Lung Neoplasms - drug therapy Lung Neoplasms - pathology Lung Neoplasms - surgery Male Neoplasm Staging Placebos Prospective Studies Quinazolines - adverse effects Quinazolines - therapeutic use Survival Rate Treatment Outcome
ISSN:	1527-7755, 1527-7755
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!